Catalog No. : SER-0710-0414

Seraseq™ Lung & Brain CNV Mix, +3 copies

Seraseq™ Lung & Brain CNV Mix, +3 copies


Copy number variations (CNV) are genomic changes that lead to higher (amplification) or lower (loss) gene copies in comparison to a reference genome. Cells that are affected by aberrant copy number changes for certain cancer-associated genes may experience disruption of normal cellular function and, ultimately, tumorigenesis.

Next-generation sequencing (NGS) can be used to determine CNVs across multiple genes in a sequencing run. However, without a widely adopted standard for CNV profiling, NGS assays may evaluate dosage for different targets using different “wet” and “dry” methods. In response, SeraCare has developed the first disease-specific CNV reference materials to support clinical labs performing NGS-based tumor profiling of cancer patient samples.

  • Single sample with three clinically-relevant CNVs (save acquisition and sequencing costs)
  • Develop, optimize, and validate your assay’s ability to detect a range of copy numbers (amplifications)
  • CNV targets precisely quantitated with digital PCR
  • Single well-characterized GM24385 human genomic DNA as background ‘wild-type’ material
  • Manufactured in GMP-compliant, ISO 13485-certified facilities

ItemSize Application Price
Seraseq™ Lung & Brain CNV Mix, +3 copies

1 × 20 µL

Next Gen Sequencing $1,069.00

# of CNVs:                            3 (full gene region for EGFR, MYCN and MET)

Copy numbers:                    + 3 copies (or 5 total copies) of each gene

Concentration:                     10 ng/µL               

Amount:                                 200 ng (single vial)

Buffer:                                    1 mM Tris / 0.1 mM EDTA pH 8.0